Source
King’s College London
The future of ATTR management
Amyloid cardiomyopathy, particularly transthyretin (ATTR) amyloidosis, has undergone a profound therapeutic transformation over the past decade. Initial strategies focused on reducing the production of misfolded transthyretin through gene silencers and stabilisers, effectively slowing disease progression and improving outcomes. However, these approaches do not address the substantial burden of pre-existing amyloid deposits within the myocardium, which continue to drive cardiac dysfunction, particularly in advanced disease.
News Url